Back to News
Market Impact: 0.42
Cue Biopharma's CUE-221 Meets Phase 2 Goals In Chronic Hives Study; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Cue Biopharma reported positive topline Phase 2a results for CUE-221 in moderate-to-severe chronic spontaneous urticaria (chronic hives). The therapy met both its primary endpoint and a key secondary endpoint, representing a meaningful clinical-development milestone that could support further advancement of the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
CUE0.88
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Snap shares fall over 10% on third-quarter earnings miss
- Leonardo raises 2026 order guidance after strong 9-mth performance
- HelloFresh Q3 core profit tops forecasts as marketing cuts hit orders
- Microsoft declines Nscale Texas expansion ahead of $35 bln IPO - report
- Hensoldt Q3 adjusted EBITDA beats forecasts, 2026 sales target raised